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Introduction
Aggressive somatic tumors possess a gene expression profile simi-
lar to embryonic stem (ES) cells, suggesting that key signaling 
pathways and biological links exist between them.1 Importantly, 
both appear to display characteristics of self-renewal and differ-
entiation potential, with current data implying that these prop-
erties underlie the resistance of cancer to genotoxic treatment 
modalities and help explain disease relapse.2,3 The characteristic 
self-renewal, extensive proliferation and differentiation potential 
of ES cells is also evident in cancer stem cells, which are highly 
proliferative and phenotypically plastic.4 The ability of cancer 
cells to utilize equivalent stem cell transcription networks is of 
Recent studies have highlighted an apparently paradoxical link between self-renewal and senescence triggered by DNa 
damage in certain cell types. In addition, the finding that Tp53 can suppress senescence has caused a re-evaluation of its 
functional role in regulating these outcomes. To investigate these phenomena and their relationship to pluripotency and 
senescence, we examined the response of the Tp53-competent embryonal carcinoma (eC) cell line pa-1 to etoposide-
induced DNa damage. Nuclear pOU5F1/OCT4a and p21CIp1 were upregulated in the same cells following etoposide-
induced G2M arrest. however, while accumulating in the karyosol, the amount of OCT4a was reduced in the chromatin 
fraction. phosphorylated ChK2 and RaD51/γh2aX-positive nuclear foci, overexpression of aURORa B kinase and 
moderate macroautophagy were evident. Upon release from G2M arrest, cells with repaired DNa entered mitoses, while 
the cells with persisting DNa damage remained at this checkpoint or underwent mitotic slippage and gradually senesced. 
Reduction of Tp53 using sh- or si-RNa prevented the upregulation of OCT4a and p21CIp1 and increased DNa damage. 
subsequently, mitoses, micronucleation and senescence were all enhanced after Tp53 reduction with senescence 
confirmed by upregulation of CDKN2a/p16INK4a and increased sa-β-galactosidase positivity. Those mitoses enhanced 
by Tp53 silencing were shown to be multicentrosomal and multi-polar, containing fragmented and highly deranged 
chromosomes, indicating a loss of genome integrity. Together, these data suggest that Tp53-dependent coupling of self-
renewal and senescence pathways through the DNa damage checkpoint provides a mechanism for how embryonal stem 
cell-like eC cells safeguard DNa integrity, genome stability and ultimately the fidelity of self-renewal.
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great interest for the subsequent understanding and treatment of 
cancer.
Recent data shows that even normal somatic cells can be repro-
grammed to become induced pluripotent stem (iPS) cells, and that 
upregulation of only a very small set of genes is sufficient to initi-
ate de-differentiation to provide them with stem-like properties. 
OCT4A (POU5F1), SOX2 and NANOG are master transcription 
factors responsible for the maintenance and tight coordination of 
pluripotency and self-renewal in ES cells.5 The first human iPS 
cells were created from somatic fibroblasts ectopically expressing 
two of these factors (OCT4A and SOX2) along with KLF4 and 
c-MYC.6 Since then, expression of OCT4A and SOX2 alone has 
been shown to be sufficient to convert human somatic cells to iPS 
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key cassette of ES cell transcription factors, OCT4A, SOX2 and 
NANOG.20,21 At the same time, these tumors are highly malig-
nant and so may be used to closely model the features of aggressive 
tumors that show ES cell transcription profiles.1,8-10 Therefore, 
in this current study, we chose to investigate the relationship 
between senescence and self-renewal regulation following DNA 
damage in the ovarian teratocarcinoma PA1 cell-line, which pos-
sesses functional TP53. For inducing DNA damage, we used the 
topoisomerase II inhibitor etoposide (ETO), which was previ-
ously used for studies of senescence in tumor and immortalized 
cells lines,15,22,23 and which is also in clinical use for the treatment 
of various cancer types.
Results
Characterization of PA-1 cells. The PA-1 cell line used in this 
study was established from the metastases of a malignant ovar-
ian teratocarcinoma. It possesses the features of embryonal 
carcinoma (EC), as testified by its ability to form OCT4A/
NANOG-positive spheres in serum-free medium (Fig. S1).24 It 
has a stable, near-diploid karyotype with a single chromosome 
translocation [t(15;20)(p11.2;q11.2)]25 and functional (although 
heterozygotic) TP53.26 Several sources show that PA1 expresses 
the key self-renewal genes OCT4A, SOX2 and NANOG.11,24,27
Response of PA-1 cells to DNA damage. To determine the 
response of PA-1 cells to DNA damage, the cells were assessed 
following ETO treatment over time. Phosphorylated CHK2 
(pCHK2) and γH2AX staining were used to report on the 
presence of DNA damage, and the cell cycle response of surviv-
ing cells was monitored using DNA cytometry. In response to 
ETO treatment, virtually all cells became arrested in G
2
 within 
2 days and displayed pCHK2 and γH2AX-positive nuclear foci 
as evidence of DNA damage and subsequently attempted DNA 
repair as judged by the presence of RAD51/γH2AX foci (Fig. 1A 
and B). The cells remained in G
2
 for up to 4 days. Simultaneously, 
small G
1
, 2C and polyploid (> 4C) cell fractions then appeared, 
increased for a few days before the polyploid fraction was over-
come by the mitotic cycling fraction and disappeared by day 7 
(Fig. 1C). Substantial apoptosis appeared from day 3, reached a 
maximum on day 5 and disappeared with the recovery of clono-
genic growth after day 7 (data not shown and Fig. 5A).
In addition, the G
2
-arrested cells showed enhanced nuclear 
staining of Aurora B kinase (Fig. S2), indicating the mitotic 
potential of these cells.
From day 3 onwards, pCHK2 nuclear staining disappeared 
in some cells, while persisting and even becoming enhanced in 
others (Fig. 1A). To elucidate which cells entered mitosis and 
which polyploidized, we examined them on day 5 using DAPI-
integrated fluorescence to assess their DNA content and size as 
well as pCHK2 nuclear staining levels. Two distinct cell types 
were observed: those with small nuclei (G
1
, 2C-sized) and those 
with large (G
2
 and polyploid, 4C and > 4C) nuclei. As seen in 
Figure 1D, the majority of large cells (≥ 4C) were pCHK2-posi-
tive, and all pCHK2-positive cells were large cells. In contrast, all 
cells with small nuclei (G
1
) were pCHK2-negative. These results 
indicate that ~30% of cells have repaired DNA and are returning 
cells.7 These results suggest that cancer cells may be able to access 
ES cell properties through the upregulation of these genes alone. 
In keeping with this proposition, the prognostic significance of 
these two markers was recently reported for several kinds of cancer 
(lung, squamous cell carcinoma, colorectal and breast).8-10
We have previously reported the upregulation of OCT4A/
SOX2/NANOG in TP53 mutant lymphoma cell lines as a 
response to DNA damage and highlighted the potential role of 
this ectopically upregulated embryonic self-renewal program as 
a survival strategy in TP53-deficient cells following genotoxic 
damage.11
Self-renewal and pluripotency factors have paradoxically also 
been linked to accelerated cellular senescence (termed senes-
cense hereon). When Banito and colleagues transfected IMR90 
human fibroblasts with the Yamanaka transcription factors 
(OCT4A, SOX2, c-MYC and KLF4), they found senescence 
was induced rather than pluripotency, which was associated with 
DNA damage.12 A study of normal IMR90 fibroblasts showed 
that at pre-senescence, cells signaling DNA damage in the ≥ 4C 
compartment simultaneously express cyclin-dependent kinase 
inhibitors p16inka4a and p21cip1, as well as the self-renewal tran-
scription factor NANOG,13 further indicating that the properties 
of pluripotency, self-renewal and senescence are tightly coordi-
nated by DNA damage.
The relationship between mitogenic activation of proliferation 
and cell senescence is also complex. For example, the concept of 
hyper-mitogenic arrest intimates that simultaneous stimulation 
of mitogen-activated pathways (integrated by mTOR) and down-
stream inhibition of cyclin-dependent kinases promotes senes-
cence.14 Similarly, DNA damage-induced senescence occurs in 
immortalized WI38 fibroblasts only when mitogenic growth fac-
tors are present.15 In this context, the role of TP53 in regulating 
proliferation and senescence is critical, with evidence of its ability 
to both block and promote senescence. On one hand, TP53 sig-
nals to prevent cellular senescence, but conversely it can cause cell 
cycle arrest, thereby providing the cellular context from which 
the senescence program can start.16 These data imply that senes-
cence is not in fact a barrier to cancer but almost a prerequisite 
for it.17 This concept and observations showing the complexity of 
the inter-regulation between these various cellular outcomes may 
help to understand how self-renewing (cancer) stem cells respond 
to DNA damage.
Together, these data indicate that intrinsic links exist between 
self-renewal, senescence and the DNA damage checkpoints of 
the cell. Further complexity arises from the fact that the regula-
tion of the cell cycle in stem cells is evidently different from that 
in normal somatic cells and not yet fully understood. Current 
reports indicate that the cell cycle in stem cells lacks G
0
, has a 
short G
1
, absent G
1
-S checkpoint18 and a preferential activation 
of the G
2
M DNA damage checkpoint, which is responsible for 
the augmented resistance of stem cells to genotoxic damage.19 
Presumably, these differences in cell cycle regulation are associ-
ated with the particular biological properties of ES cells, such as 
self-renewal (immortality).
EC cell lines, which are derived from germ cell tumors, can 
serve, to a certain extent, as a model of ES cells and express the 
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recovering mitotic cells and clones (Fig. S4A). In contrast, rare 
cells expressed high levels of NANOG in both control and ETO-
treated conditions (Fig. S4B). The NANOG-overexpressing cells 
observed after ETO treatment were large and presumably poly-
ploid. We hypothesize that they arose by overcoming the G
1
−4N 
checkpoint and avoiding senescence. These cells have the poten-
tial to reach 8–16C and then de-polyploidize. Such a response is 
typical of mutant TP53 lymphoma cells after DNA damage,11,29 
but is a rare event with PA-1.
Upregulation of OCT4A and P21CIP1 in response to 
DNA damage. We next assessed key molecular regulators of 
the DNA damage response by immunofluorescence (IF). As 
expected, TP53 and, subsequently, P21CIP1 (CDKN1A), were 
upregulated in response to ETO treatment. However, the plu-
ripotency self-renewal transcription factor OCT4A was also 
upregulated (Fig. 2A–C). In fact, paradoxically, OCT4A and 
P21CIP1 were shown by IF to be both expressed in the same 
cells (Fig. 2B and C). Expression of high levels of both proteins 
to the mitotic cell cycle, while the remainder display persistent 
DNA damage and are either maintained in the 4C fraction or 
become polyploid.
During this period, macroautophagy was observed in 
response to ETO treatment as seen by LC3B and P62 lysosomal 
staining being compatible with the enhanced OCT4A stain-
ing (Fig. S3A– D) and gradually increasing from day 1 to 5. 
Macroautophagy returned to resting levels in cells as they re-
entered mitotic cycling, but remained elevated in cells that per-
sisted in G
2
 and in most polyploid cells. TERT staining revealed 
nuclear foci in NT cells (not shown) and in the small cells re-
entering the mitotic cycle following ETO treatment. Most large 
cells lacked nuclear foci and showed elimination of TERT in 
perinuclear LC3B-lined vacuoles; however, in parallel, large 
amounts of TERT also appeared in their cytoplasm (Fig. S3E 
and F), possibly due to the stress-protecting binding of TERT 
to mitochondria.28 Most PA-1 cells displayed low NANOG 
expression, which was more evident around chromosomes in 
Figure 1. DNa damage response of pa-1 cells to eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and assessed at the 
indicated time point. Cells were pelleted, cytospun, fixed and stained for (A) pChK2 (red) or (B) γh2aX (red) and RaD51 (green) in combination with 
DapI (blue). Bar = 10 μM. (A) NT pa-1 cells show very faint background pChK2 staining in non-dividing cells and increased staining of centrosomes in 
dividing cells (white arrowheads). On day 2 post-eTO, small pChK2-positive foci accumulate in the nuclei of all cells. By day 4, some small nuclei have 
lost pChK2 staining (yellow arrowheads), while large cells remain pChK2 positive. (B) NT pa-1 cells show no positive staining for γh2aX or RaD51. On 
day 2, the majority of cells show accumulation of γh2aX or RaD51 positive foci in the nuclei. (C) Cells were cytospun, fixed and stained for DNa image 
cytometry. DNa content was determined for at least 200 cells in each condition and represented as a percentage. profound G2 arrest on day 2 was 
observed followed by the simultaneous emergence of a polyploid (> 4C) and G1 fraction on day 5 before the recovery of the normal cell cycle profile 
by day 7. (D) The proportion of pChK2-positive cells was examined in the context of DNa content with cells sub-divided into small or large cells. In the 
NT control sample, all cells were pChK2-negative with an expected nuclei size distribution (2C 80%; ≥ 4C 20%). On day 2, all cells were pChK2-positive 
and the vast majority of nuclei were large (≥ 4C). By day 5, cells with small nuclei appear, all of which are pChK2-negative. Data are representative of > 
three independent experiments.
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treatment, both TP53 and OCT4A levels partially decreased, 
while P21CIP1 continued to increase. Transfection of PA-1 
cells with TP53-siRNA successfully silenced TP53 expression 
throughout the time-course and, as expected, inhibited the 
increase in P21CIP1 in response to ETO treatment. However, 
unexpectedly, silencing of TP53 also largely inhibited the upreg-
ulation of OCT4A. Thus, the increase in OCT4A in response 
to ETO is largely TP53-dependent. To confirm this surprising 
finding, we repeated these experiments using PA-1 cells stably 
transfected with a shRNA vector directed against a different 
region of TP53 and saw the same results (Fig. S6) with dimin-
ished OCT4A upregulation.
Previous studies have indicated that the expression of OCT4A 
in cancer cell lines may have been misreported due to the presence 
displayed a strong positive correlation (Fig. 2D) in the first 3 days 
post-treatment in the G
2
 (4C by DNA content) and polyploid 
(> 4C) fractions described above (Fig. 2E; Fig. S5A). However, 
individual cells were shown to vary greatly in their expression of 
both of these factors after treatment as indicated by their mean 
expression levels, standard deviations and extended outliers 
(Fig. 2D; Fig. S5B).
The TP53 dependency of the OCT4A response. To fur-
ther investigate the link between increased OCT4A expression 
and TP53 induction after DNA damage in PA-1 cells, siRNA 
directed against TP53 was used. Western analysis of whole-cell 
lysates confirmed that ETO treatment strongly upregulated 
TP53, OCT4A and P21CIP1 (CDKN1A), confirming our IF 
results (Fig. 3). In the post-G
2
 period, from day 4 after ETO 
Figure 2. Regulation of Tp53, p21CIp1 and OCT4a in pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and 
assessed at the indicated time point. Cells were pelleted, cytospun, fixed and stained for (A) Tp53 (red) (B) p21CIp1 (red) or (C) p21CIp1 (red) and OCT4a 
(green) in combination with DapI (blue); Bar = 10 μM. Results representative of nine separate experiments. (A) NT cells showed very faint background 
staining for Tp53. On day 3 post-eTO treatment, Tp53 accumulated in the majority of nuclei. (B and C) NT cells had faint background staining for 
p21CIp1 and weak staining of OCT4a. On day 3 post-eTO treatment, p21CIp1 and OCT4a accumulated in the majority of cell nuclei. (D) Using image 
analysis on fixed cytospins, the fluorescence intensity of p21CIp1 and OCT4a during the first 3 d post-eTO treatment was determined and plotted 
for 500 cells in four independent experiments. There was substantial increase and a clear positive correlation between the fluorescent intensity of 
staining for OCT4a and p21CIp1 after eTO treatment. at the same time, the amplitude of the expression of both factors greatly increased: Non-treated 
OCT4a expression mean = 2,448, sD = 1,236; OCT4a expression on day 3 mean = 12,641, sD = 6,189; non-treated p21CIp1 expression mean = 2,875, sD 
= 1,594; p21CIp1 expression on day 3 mean = 10,291, sD = 5,795. (E) Two-channel flow cytometry was used to measure DNa content (pI fluorescence) 
and OCT4a expression. In NT samples, the OCT4a expression was similar in the 2C and 4C fractions. after eTO treatment, OCT4a was highly elevated 
in the 4C and 8C fractions and to a lesser extent in the G1−2C fraction. These data indicate that OCT4a accumulation was mostly induced in the DNa 
damage checkpoint and persisted in the polyploid cells.
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encoding HA-tagged forms of OCT4A or OCT4-pseudogene 1 
were produced, transfected into HEK-293 cells and the ability of 
OCT4 antibodies to detect them examined. It was revealed that 
although both proteins were equivalently expressed as judged by 
detection with anti-HA antibodies, only the OCT4A form was 
detected with the anti-OCT4A monoclonal antibody reagent 
(Fig. S7). Together, these data confirm that the increase in 
OCT4A described here was attributed to bona fide OCT4A and 
not alternative splicing or pseudogene forms. However, it should 
be noted that an additional smaller protein species of OCT4A 
was also observed in our experiments, which increased in inten-
sity in response to ETO treatment. As discussed above, the size of 
this protein does not correspond to OCT4B1, nor does this anti-
body detect other isoforms of OCT4. It therefore may reflect a 
of other OCT4 isoforms (OCT4 B, B1 and/or transcribable pseu-
dogenes-1, -3 and -4). To address this issue here, we performed 
RT-PCR and revealed that OCT4A transcription was present 
but not particularly enhanced after ETO treatment (Fig. 4A), 
whereas isoform B was entirely absent. The splicing isoform 
OCT4 B1 (characteristic for ES/EC cells and poorly differen-
tiated cancer)30,31 was induced after ETO treatment (Fig. 4A). 
In addition, our results indicated that pseudogene-1 was tran-
scribed, whereas pseudogenes-3 and -4 were not (not shown). 
The OCT4B1 splicing form is appreciably smaller in size in com-
parison to OCT4A, and was not detected in our immunoblot-
ting analysis with either OCT4A or OCT4A/B antibodies and so 
can be disregarded. However, to evaluate our IF and immunob-
lotting findings in relation to pseudogene-1, expression vectors 
Table 1. primary antibodies
Target Description Specifity/immunogen
Product nr and  
manufacturer
Use*
Tp53 Rabbit polyclonal against full-length human p53 fusion protein
#9282 Cell signalling 
Technology
W, IF
OCT Mouse mab
peptide raised against amino acids 1–134 of OCT-3/4 
of human origin non-cross-reactive with OCT-3/4 iso-
forms B and B1.
sc-5279, santa Cruz W, IF, F
OCT4a/B
Rabbit polyclonal, ChIp 
grade
peptide derived from within residues 300 to  
the C terminus of human OCT4.
ab19857,  abcam W, IF, F
NaNOG
Mouse mab, clone 
NNG-811
against human NaNOG. N3038, sigma IF
p16INK4a Rabbit polyclonal human p16, C-terminal. ab7962, abcam IF
p16INK4a Rabbit polyclonal
Raised against a peptide mapping at the N terminus of 
p16 of human origin.
sc-467, santa Cruz W, IF
aURORa B kinase Rabbit polyclonal
peptide derived from within residues 1–100 of human 
aURORa B.
ab2254, abcam IF
Telomerase reverse tran-
scriptase (TeRT)
Mouse mab against human TeRT. ab5181, abcam IF
p62 (sQsTM1) Rabbit polyclonal
epitope corresponding to amino acids 151–440 of 
sQsTM1 of human origin.
sc-25575, santa Cruz IF
pChK2 
 (phosphorylated T68)
Rabbit polyclonal
epitope around the phosphorylation site of Threonine 
68 (VsT pQe) of human ChK2.
ab38461, abcam W, IF
α-tubulin Mouse mab
Recognizes an epitope located at the C-terminal end of 
the α-tubulin isoform in a variety of organisms.
T5168, sigma IF
γ-h2aX Rabbit polyclonal
Recognizes mammalian, yeast, D. melanogaster  
and X. laevis γ-h2aX.
4411-pC-100, Trevigen IF
RaD51 Mouse mab Targeted to amino acids 1–138 of human RaD51. ab213, abcam IF
LC3B Rabbit polyclonal
peptide derived from within residues 1–100 of human 
LC3B.
ab63817, abcam IF
p21CIp1 Rabbit polyclonal
Raised against a peptide mapping at the C terminus of 
p21 of human origin.
sc-397, santa Cruz W, IF
GapDh Mouse mab, clone 6C5 Rabbit muscle GapDh. ab8245, abcam W
β-actin Rabbit polyclonal
synthetic peptide derived from within residues 1–100 
of human β-actin.
ab8227, abcam W
*W, western; IF, immunofluorescent staining; F, flow cytometry.
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enumerated (for examples of normal and abnormal patterns, see 
Fig. S9). The results of this analysis showed that all mitoses in 
TP53-silenced samples were multicentrosomal and most of them 
multipolar, with a smaller proportion showing coalescence of 
multiple centrosomes at two poles, indicating a high degree of 
chromosome and centrosome instability (Fig. 6A). Conversely, 
the mitoses in control cells after ETO treatment were mostly 
bipolar and bicentrosomal, with a smaller proportion of multi-
centriolar multipolarity. Inspection of metaphases by DNA stain-
ing after TP53 silencing revealed that they were highly aberrant 
with deranged plates, partly uninemic, fragmented and clumped 
chromosomes and no anaphases, while only rare aberrant mitoses 
were seen in the control sample (characteristic patterns are shown 
in Fig. S10A and B). Some of these aberrant metaphase plates 
in ETO-treated controls had chromosomes separated from the 
mitotic spindle and, when stained for γH2AX, displayed DNA 
damage (Fig. S10C). Intense DNA damage was also observed 
in the polyploid cells with micronuclei, while cells with small 
nuclei were free of γH2AX staining or contained only residual 
damage (Fig. S10D). Presumably, these observations explain the 
link between damaged DNA, aberrant mitoses, spindle check-
point arrest and the induction of polyploidy by mitotic slippage. 
Therefore, we conclude that in spite of increased entrance into 
mitosis after TP53 silencing, these cells are arrested in metaphase 
and delay proliferation, enhancing their propensity to undergo 
mitotic slippage, and become tetraploid. However, the eventual 
recovery of the cell population from small clones re-entering 
mitosis was comparable in both TP53-silenced and control cells, 
suggesting that TP53-silenced cells compensate for their initial 
delay in proliferation.
Effect of TP53-silencing on micronucleation. Next, we 
examined the effect of TP53-silencing on chromosome stabil-
ity using the presence of micronuclei as a marker (Fig. 6B). As 
expected, treatment with ETO caused an increase in micronu-
cleation and, thus, nuclear instability. Chromosome instability 
was substantially increased by silencing of TP53 as judged by the 
~4-fold increase in micronucleation index.
Effect of TP53-silencing on senescence. Subsequently, 
we addressed how TP53 affected the induction of senescence 
after ETO treatment, initially by assessing the expression of 
P16INKA4A. We found that an increase in P16INKA4A expres-
sion was detected from days 4–5 post-treatment in TP53-silenced 
cells (Fig. 7A), corresponding with the partial release from G
2
 
arrest and increase in (aberrant) mitoses. In contrast, mock-trans-
fected control cells had only marginal expression of P16INKA4A 
during this time. To confirm whether the increase in P16INKA4A 
expression corresponded with other indicators of senescence, 
senescence-associated β-galactosidase (sa-β-gal) staining and 
morphological analysis were performed. In control cells, ETO 
treatment evoked a modest but measurable increase in cell size 
(hypertrophy) and weak sa-β-gal staining at later time points. 
However, this was greatly accelerated by the silencing of TP53 
with strong sa-β-gal staining in a significantly (p < 0.05, n = 3) 
higher proportion of cells in TP53-silenced (mean = 70.7%) vs. 
control (mean = 38.7%) samples at day 5 post-treatment, corre-
sponding with the accelerated increase of DNA damage marked 
post-translational change in OCT4A that increases in response 
to DNA damage.
OCT4A does not bind chromatin during the DNA dam-
age response. Subcellular fractionation was subsequently used to 
establish the location of the OCT4A within the cell. Cytoplasm, 
membrane-bound, nuclear (karyosolic) and chromatin-bound 
fractions were obtained, and OCT4A presence was assessed by 
immunoblotting. This analysis revealed a considerable increase 
of OCT4A in response to ETO treatment in the nuclear (karyo-
solic) fraction as attested to by two different antibodies, directed 
to the N or C terminus of OCT4. However, OCT4A was shown 
to be depleted after ETO treatment from the chromatin-bound 
fraction as compared with non-treated cells (Fig. 4B), indicating 
that although it is elevated, it may lack the ability to bind its own 
promoter or the promoters of its cooperative partners (SOX2 and 
Nanog) and influence the downstream transactivation targets.
Effect of TP53 on the cell cycle response. We next sought to 
examine the effect of TP53 on the cell cycle response of PA-1 cells 
after ETO treatment using flow cytometry and DNA image anal-
ysis (Fig. 5A–C). As indicated above using DNA image cytom-
etry, ETO treatment of TP53-competent PA-1 cells resulted in a 
pronounced G
2
 arrest by day 1–2, followed by its release from day 
3–4 and a degree of polyploidy and apoptosis. When TP53 was 
silenced by shRNA in transfected cell lines, a larger proportion of 
cells accumulated in the 4C and polyploid fractions. Subsequently, 
less cells recovered in the G
1
-2C fraction (Fig. 5A and B). These 
relationships were more evident upon DNA image analysis that 
omitted apoptotic cells (Fig. 5C; Fig. S8). Surprisingly, despite 
an apparent delay in proliferation, mitotic counts revealed a 
significant increase in the mitotic index (MI) of TP53-silenced 
samples compared with TP53-sufficient controls. (Fig. 5D; and 
shown for an individual experiment in Fig. 5C). To address the 
nature of this response further, pCHK2 and α-tubulin staining 
was performed on adherent cells on day 4 after ETO treatment. 
Using this approach, bipolar and bicentrosomal mitotic cells 
and aberrant multipolar mitotic cells were distinguished and 
Figure 3. Immunoblot analysis of Tp53, OCT4a and p21CIp1 in pa-1 cells 
after eTO treatment. pa-1 cells were treated with non-target (ntg) siRNa 
(−) or siRNa-Tp53 (+) for 24 h before treatment with 8 μM eTO, washing 
after 20 h and cell lysates made and assessed by immunoblotting for 
Tp53, p21CIp1, OCT4a or GapDh as a loading control at the indicated 
time points (day 3 and day 5). Tp53 was upregulated in response to eTO 
treatment and suppressed by siRNa-Tp53. p21CIp1 and OCT4a were also 
upregulated by eTO treatment, and the upregulation was restricted by 
treatment with siRNa-Tp53. Data are representative of three indepen-
dent experiments.
436 Cell Cycle Volume 12 Issue 3
to enter mitosis, so retained a clear plasticity of response, not yet 
terminally committed to senescence.
The DNA damage response in the PA-1 cells appears to couple 
the upregulation of the pluripotency and self-renewal-promoting 
master molecule, OCT4A, with cell cycle arrest and senescence-
promoting molecules (TP53 and P21CIP1) in the same cells, pro-
viding them with bipotentiality in the DNA damage checkpoint. 
Furthermore, the expression levels of these proteins in individ-
ual cells after treatment was highly varied. Although heteroge-
neous expression of NANOG within ES cell cultures has been 
observed,32 and this, in turn, has been attributed to fluctuation of 
NANOG levels,33 it is generally accepted that OCT4A expression 
is tightly regulated and expressed relatively uniformly in ES cell 
populations and does not fluctuate.34 In the context of TP53-
dependent upregulation of OCT4A, the heterogeneity observed 
here may be due to fluctuation in TP53 expression itself, which is 
well-documented in cell stress responses.35,36
Artificially reducing the level of TP53 using si- or shRNA 
resulted in precocious mitosis and, subsequently, an increase in 
chromosome and centrosome instability in response to ETO 
treatment. In addition, TP53 silencing caused an increase in 
DNA damage and enhanced senescence. This is in agreement 
with previous studies that demonstrated TP53 can suppress cel-
lular senescence.16 We therefore propose that unrepaired DNA 
damage and the increase in chromosome instability may link 
TP53 suppression to senescence.
by pCHK2 (Fig. S6) and the senescence marker P16INKA4A 
(Fig. 7A) seen above.
Discussion
In this study, we investigated the DNA damage response of the 
ovarian teratocarcinoma cell line PA-1, with particular focus on 
the relationship between self-renewal and senescence and the role 
of TP53 in regulating these different cell fates. Despite express-
ing functional TP53, PA-1 cells showed a preferential G
2
M arrest 
following ETO-induced DNA damage, a characteristic feature 
and cause of genotoxic resistance of ES cells.19 We also observed 
equivalent results with other forms of DNA damage such as X-ray 
irradiation (data not shown).
This arrest was typically characterized by extensive DNA 
damage signaling (indicated by the upregulation pCHK2 and 
γH2AX) and by attempted repair through homologous recom-
bination (as shown by the induction of RAD51/γH2AX foci). 
The subsequent cellular response varied: while most cells died, 
some cells successfully repaired, halted DNA damage signaling 
and returned to mitotic cycling, whereas others displayed persis-
tent DNA damage, remained in the 4C fraction or became poly-
ploid. These latter cells underwent upregulated macroautophagy, 
indicative of a move toward senescence. However, these cells were 
also OCT4A and AURORA B kinase-positive, contained a large 
amount of cytoplasmic TERT and were therefore potentially able 
Figure 4. analysis of OCT4 regulation in pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then washed and examined at 
the indicated time points by (A) semi-quantitative pCR or (B) cell fractionation and immunoblotting using antibodies against OCT4a or OCT4a and B, 
actin or histone h3 (h3), the latter two as loading controls. (A) OCT4a transcription was shown to be modestly upregulated in response to eTO after 3 
d (upper panel). OCT4B was not substantially detected (middle panel). OCT4B1 was upregulated in response to eTO. OCT4-pG-1 was also upregulated 
in response to eTO (lower panel). Controls were NTC, non-template control; pBL, peripheral blood lymphocytes. equivalent amplification of actin 
after 30 cycles was used as a control for cDNa input (bottom panel). Data representative of three independent experiments. (B) OCT4a protein was 
upregulated in response to eTO treatment in the cytosol, membrane and nuclear fractions. OCT4a was downregulated in the chromatin-bound frac-
tion. No additional bands were detected with the OCT4a/B dual specificity (C-terminal) antibody compared with the mono-specific OCT4a antibody 
(N-terminal), indicating only OCT4a species are expressed. Data representative of two independent experiments.
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chromosome and centrosome instability and, thus, safeguards 
the fidelity of self-renewal in the damage-resistant EC cells.
The question again follows, how are these opposing processes 
coordinated at the molecular level? The explanation may be 
provided by the observation that the OCT4A induced by TP53 
at the DNA damage checkpoint is unable to bind chromatin. 
Presumably then, OCT4A is unable to execute its transactiva-
tion role in binding to the NANOG promoter regulatory ele-
ment essential for the pluripotency function.34,38 Conversely, 
the NANOG promoter should be directly blocked by activated 
TP53.39 However, importantly, in ETO-treated PA-1 cells, 
The question then becomes how. Precocious aberrant mitoses 
containing DNA damage readily undergo mitotic slippage (to 
become G
1
-4N cells with micronuclei), which may undergo apop-
tosis or alternatively trigger terminal senescence through TP53-
independent P21CIP1 and P16INKA4A targeting of the cyclin 
kinases governing the G
1
−S transition. Weaver and Cleveland 
also suggested adaptation of the spindle checkpoint as a path-
way to cell survival vs. senescence through tetraploidy.37 Based 
upon our observations, we suggest that coupling the expression 
of self-renewal and senescence regulators through TP53 at the 
DNA damage checkpoint favors DNA damage repair, reduces 
Figure 5. effect of silencing Tp53 on the cell cycle response of pa-1 cells after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, then 
washed and examined at the indicated time points by (A and B) flow cytometry, (C) DNa image cytometry and (D) mitotic counts. (A) Both control 
plasmid and shRNa p53-silenced cells undergo a G2M arrest after eTO treatment, which is, however, more profound from day 3 in Tp53-silenced cells. 
The Tp53-silenced cells also show a larger increase in the ≥ 4C cell fraction in response to eTO treatment. Conversely, the recovering G1−2C fraction is re-
duced. By day 5, the relative proportion of the G2 fraction is diminished in both samples, due to the increase in apoptosis. (B) The proportion of cells in G2 
was enumerated over the time course in three independent experiments with the mean and seM plotted (* p < 0.05). (C) DNa image cytometry analysis 
was also performed on day 4 after eTO treatment. apoptotic cells were excluded from the measurements, and highlighted more clearly the relationship 
between the increased 4C fraction and relative delay in recovery of the proliferating G1−2C fraction (reduced 2.5-fold) after Tp53-silencing. The cor-
responding mitotic index (MI) at this time point is also shown. For full cell cycle dynamics over the time course in this experiment, please see Figure S6. 
Data representative of two similar experiments. (D) Mitotic counts were performed on control plasmid or shRNa p53-silenced cells over time after eTO 
treatment. The results from three independent experiments show a significant increase in the proportion of mitoses after Tp53 silencing (* p < 0.05).
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stable cell lines established and maintained in media containing 
puromycin. Selection was removed 3 d prior to experiments.
Expression of HA-tagged forms of OCT4A and OCT4A-
pseudogene-1. Expression vectors encoding HA-tagged forms 
of OCT4A or OCT4A-pseudogene-1 (OCT4A-PG1), a kind 
gift from Professor Aijun Hao,43 were transfected into HEK-293 
cells using Fugene 6 (Promega) according to the manufacturer’s 
protocol.
DNA image cytometry. Cytospins were prepared and fixed 
in ethanol:acetone (1:1) for > 30 min at 4°C and air-dried. Slides 
were then treated with 5N HCl for 20 min at room temperature, 
washed in distilled water (5 × 1 min) and stained for 10 min 
with 0.05% toluidine blue in 50% citrate-phosphate McIlvain 
buffer pH 4. Slides were rinsed with distilled water, blotted dry 
and dehydrated by incubating twice in butanol for 3 min each 
at 37°C. Samples were then incubated twice in xylene for 3 min 
each at room temperature before being embedded in DPX. Slides 
were then evaluated using a Leitz Ergolux L03-10 microscope 
equipped with a calibrated Sony DXC 390P color video camera. 
OCT4A accumulates in the cell nucleus, and this should be a pre-
requisite for its effective upregulation of NANOG through a pos-
itive feedback loop, when the NANOG promoter becomes free 
from inhibition by TP53 after DNA damage repair. Therefore, 
accumulation of OCT4A can be considered as a precursor for 
self-renewal potential. Simultaneously, the cell is primed for 
senescence through the accumulation of P21CIP1, again in a 
TP53-dependent manner, but is prevented from its full execu-
tion, possibly by the pre-mitotic molecular environment of the G
2
 
cell. It follows that the PA-1 cells in the G
2
M damage checkpoint 
are in a state of bi-potential metastability between self-renewal 
and senescence, akin to the situation of bi-potentiality between 
self-renewal and differentiation in stem cells.
This interpretation fits well with the extensive heterogeneity 
in OCT4A and P21CIP1 levels observed in the individual cells 
held at the G
2
 arrest, potentially suggesting that their expres-
sion levels are dynamically fluctuating.40 To our knowledge, this 
notion of bi-potential metastability has not previously been con-
sidered as a key result of DNA damage, and we believe our data 
support further study of this area.
In conclusion, our studies have described two previously 
unknown phenomena relating to the intrinsic link between self-
renewal and senescence in DNA damaged cells expressing stem 
cell-like transcriptional networks and revealed the role of TP53 
in this process. This knowledge may be of use in improving our 
understanding of normal stem cells and also in designing better 
strategies to eliminate cancer stem cells.
Materials and Methods
Cell culture and ETO treatment. PA-1 (ATCC) and HEK-
293 cells were cultured in Dulbecco’s modified Eagle’s media 
(DMEM) supplemented with 10% fetal calf serum. Cells were 
grown without antibiotics in 5% CO
2
 incubators at 37°C. For 
the sphere formation assay, PA1 cells were inoculated in DMEM/
F12 media supplemented with 20 ng/ml EGF (236-EG, R&D 
Systems), 10 ng/ml FGF (233-FB-025/CF, R&D Systems), 
0.5 ng/ml hydrocortisone (H0888, Sigma), 10 ng/ml insu-
lin (I9278, Sigma), 1× antibiotics/antimycotics (15240-062, 
Invitrogen), 1% L-glutamine (25030024, Invitrogen) and 20% 
methylcellulose (high viscosity, 4,000 cP; M0512, Sigma), and 
grown in 5% CO
2
 at 37°C. Exponentially growing PA-1 cells 
were incubated with an 8 μM dose of ETO for 20 h.
Small interfering RNA (siRNA). TP53 protein Hs_TP53_9 
FlexiTube siRNA (Qiagen) was used to silence TP53 expression 
and ON-TARGET plus non-targetting siRNA #1 (Dharmacon) 
was used as a negative control. PA-1 cells were transfected with 
siRNA using HiPerfect (Qiagen) according to the manufacturer’s 
protocol.
Small hairpin RNA (shRNA). The following plasmids were 
purchased from Addgene: pMKO.1 puro TP53 plasmid (Addgene 
plasmid 19119) deposited by Bob Weinberg;41 and pMKO.1 puro 
(Addgene plasmid 8452) deposited by Bob Weinberg.42 PA-1 cells 
were transfected with plasmid using Fugene 6 (Promega) accord-
ing to the manufacturer’s protocol and then selected using puro-
mycin (0.3 μg/ml). After 2 wk, growing colonies were sub-cloned, 
Figure 6. effect of silencing Tp53 on genome instability in pa-1 cells 
after eTO treatment. pa-1 cells were treated with 8 μM eTO for 20 h, 
then washed and examined at the indicated time points for the (A) the 
proportion of normal (2 centrosomal; 2 cen), ≥ 4 cen bipolar and ≥ 4 
cen multipolar mitoses and (B) micronucleation. (A) Cells were treated 
as before and then examined by IF staining for pChK2 and α-tubulin. 
silencing of Tp53 caused multi-centrosomal mitoses (≥ 4 cen) that were 
mostly multi-polar or showed coalescence of centrosomes in two poles. 
(B) Cells were treated as before and then assessed for the extent of 
micronucleation following DNa in situ staining. an increase in the pro-
portion of interphase cells with micronuclei was observed in response 
to eTO treatment. silencing of Tp53 significantly increased the amount 
of micronucleation, which was further enhanced in response to eTO 
(p < 0.05). Data are representative of three independent experiments.
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DNA flow cytometry. Cells were trypsinized, har-
vested at indicated time points, washed in PBS and sus-
pended in hypotonic fluorochrome solution [50 μg/ml 
propidium iodide (PI), 0.1% (w/v) sodium citrate, 0.1% 
(v/v) Triton X-100] and stored for at least 1 h in the dark 
at 4°C. Flow cytometry was performed using a FACScan 
(BD Biosciences) using Cell Quest Pro Software.
Two-channel flow cytometry. Cells were harvested at 
relevant time points, washed in cold PBS and fixed with 
70% ethanol for 20 min at room temperature. After two 
washes in TBS, cells were permeabilized with TBS/4% 
bovine serum albumin (BSA)/0.1% Triton X-100 for 10 
min at room temperature. Samples were then incubated 
with rabbit polyclonal anti-OCT4 antibody solution 
(ab19857, Abcam) (5 μg/ml) in TBS/4% BSA/0.1% 
Triton X-100 for 1 h at room temperature. Following two 
washes in TBS, cells were incubated with goat anti-rabbit 
Alexa Fluor 488 solution (1:200) in TBS/4% BSA/0.1% 
Triton X 100, for 30 min in the dark. DNA was coun-
terstained with 10 μg/ml PI solution in PBS, containing 
200 μg/ml RNase (Sigma) and assessed by flow cytometry 
using a FACS Calibur (BD Biosciences) using Cell Quest 
Pro Software.
Immunofluorescent (IF) staining. IF was performed 
as described previously.44 Cytospins were fixed in metha-
nol for 7 min at −20°C and dipped 10 times in ice-cold 
acetone. Slides were then washed three times in TBS 
0.01% Tween 20 (TBST) for 5 min. Slides were subse-
quently blocked for 15 min in TBS, 0.05% Tween 20%, 
1% BSA at room temperature. Samples were covered with 
50 μL of TBS, 0.025% Tween 20%, 1% BSA contain-
ing primary antibody and incubated overnight at 4°C in 
a humidified chamber. Samples were then washed three 
times in TBST and covered with 50 μL of TBST contain-
ing the appropriate secondary antibody before incubation 
for 40 min at room temperature in the dark. Slides were 
washed three times for 5 min with PBST and once for 
2 min in PBS. Samples were then counterstained with 
0.25 μg/ml DAPI for 1 min, mounted using ProLong 
Gold antifade reagent (Invitrogen) and evaluated using a 
Leitz Ergolux L03-10 microscope equipped with a Sony 
DXC 390P color video camera. Antibodies and their 
source are listed in Tables 1 and 2. Note: when stain-
ing for tubulin, the fixation step using acetone was omit-
ted and detergent was absent from all buffers. For TERT 
staining alone, the fixed cells were pre-treated with 2N 
HCl for 20 min at room temperature.
Detection of sa-β-galactosidase activity. The senes-
cence β-galactosidase (sa-β-gal) staining kit (Cell 
Signaling, 9860) was used to detect sa-β-gal activity in 
cultured cells at indicated time points according to the manufac-
turer’s protocol.
Western blotting (whole-cell lysate). Cells were harvested 
using trypsin digestion and lysed using RIPA buffer with prote-
ase inhibitor cocktail (Sigma P8340). Total protein was quanti-
fied using BCA protein assay kit (Pierce) and equal quantities 
DNA content was measured as the integral optical density in 
the green channel, using Image-Pro Plus 4.1 software (Media 
Cybernetics). Apoptotic cells were omitted from measurements. 
The stoichiometry of DNA staining was verified using the values 
obtained for metaphases compared with anaphases and telophases 
(ratio 2.0); the method error was estimated to be less than 5%.
Figure 7. senescence response of pa-1 cells to eTO treatment. pa-1 cells stably 
transfected with shRNa-p53 or plasmid control were treated with 8 μM eTO for 
20 h, then washed and assessed at the indicated time point by (A) immunoblot-
ting or (B) for sa-β-gal expression and cellular morphology. (A) Cell lysates were 
made and assessed by immunoblotting for p16INKa4 and GapDh as a loading 
control. an accumulation of p16INKa4 was detected in Tp53-silenced cells 
after eTO treatment. (B) sa-β-gal staining was used to detect sa-β-gal activity 
in response to eTO treatment at indicated time points. Detection of sa-β-gal 
activity was increased by Tp53-silencing and largely mirrored the induction of 
p16INKa4 seen above. (C) higher power image of the cells seen on day 5.  
Bar = 20 μM. Data are representative of > three independent experiments.
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identity determined by direct sequencing after ExoI/SAP treat-
ment (Fermentas, MBI) using the fluorescent Big DyeTerminator 
v. 3.1 Cycle Sequencing protocol on a 3,130 xl Genetic Analyzer 
(Applied Biosystems).
Methods of statistical analysis. Statistical analysis was per-
formed in Minitab. A paired t-test was used to calculate the sta-
tistical significance of difference of means where appropriate. 
Statistical significance was accepted when p < 0.05. Graphs were 
plotted in GraphPad Prism 5 and Statistica 6.
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of denatured protein were subjected to electrophoresis on SDS-
polyacrylamide gels, blotted onto Immobilon-FC transfer mem-
brane and probed with specific primary antibodies listed in Table 
1 and secondary antibodies listed in Table 2. The signal was visu-
alized using a LICOR Odyssey imaging system.
Subcellular fractionation. For cellular fractionation, the 
Subcellular Protein Fractionation Kit for Cultured Cells 
(Thermo Scientific) was used according to the manufacturer’s 
instructions. Cytoplasmic, membrane, nuclear soluble, karyosol 
and chromatin-bound protein extracts were obtained. Protein 
concentrations were determined by Bio-Rad (Bio-Rad Inc.) pro-
tein assay, using a BSA standard set (Fermentas MBI) for quanti-
tation. Proteins (10 or 15 μg) were separated on 10, 12, 5 or 20% 
SDS PAGE gels, followed by electrophoretic transfer onto BA85 
nitro-cellulose membranes (Schleicher and Schuell GmbH) over-
night. Equal protein loading in each lane was verified by Ponceau 
S staining. Blots were probed with specific primary antibodies 
listed in Table 1 and secondary antibodies listed in Table 2. The 
signal was visualized using the Chemiluminescent Nucleic Acid 
Detection Module (Thermo Scientific).
RT-PCR analysis of Oct4-splicing forms. Total RNA was 
extracted from cells using TRIZOL (Invitrogen). cDNA was 
synthesized using First Strand cDNA Synthesis Kit (Fermentas 
MBI) according to the manufacturer’s protocol and then diluted 
10×. The absence of contamination with genomic DNA was 
verified by PCR using actin primers as described.11 cDNA from 
peripheral blood lymphocytes (PBL) as a control of somatic cells 
was kindly provided by Dr Inta Vasiljeva. Amplification was per-
formed with 1–4 μl of diluted cDNA and the following prim-
ers, β-actin F/R; Oct4A AF/AR; Oct4B/B1 BF1/BR2 under 
conditions previously described.11 Amplified PCR products were 
analyzed on an agarose gel after various PCR cycles and their 
Table 2. secondary antibodies
Antibody Conjugate Product nr and manufacturer Use*
Goat anti-mouse IgG alexa Fluor 488 a31619, Invitrogen IF, F
Goat anti-rabbit- IgG alexa Fluor 594 a31631, Invitrogen IF
Goat anti-rabbit IgG hRp 32460, Thermo Fisher scientific W
Rabbit anti-mouse IgG hRp 61-6520, Invitrogen W
Goat anti-rabbit IgG IRDye 800CW 926-32211, IRDye antibodies W
Goat anti-mouse IgG IRDye 800CW 926-32210, IRDye antibodies W
Goat anti-rabbit IgG IRDye 680LT 926-68021, IRDye antibodies W
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